The SYMPLICITY HTN-1 and HTN-2 studies showed that renal denervation （RDN） is feasible as a novel treatment for resistant hypertension. Despite great enthusiasm toward this new treatment modality, until now the curr...The SYMPLICITY HTN-1 and HTN-2 studies showed that renal denervation （RDN） is feasible as a novel treatment for resistant hypertension. Despite great enthusiasm toward this new treatment modality, until now the current evidence rests on only one randomized controlled trial. SYMPLICITY HTN-3 is a pivotal study started for regulatory purposes in the United States with the goal to evaluate the efficacy and safety of RDN in treatment of resistant hypertension.展开更多
文摘The SYMPLICITY HTN-1 and HTN-2 studies showed that renal denervation （RDN） is feasible as a novel treatment for resistant hypertension. Despite great enthusiasm toward this new treatment modality, until now the current evidence rests on only one randomized controlled trial. SYMPLICITY HTN-3 is a pivotal study started for regulatory purposes in the United States with the goal to evaluate the efficacy and safety of RDN in treatment of resistant hypertension.
